©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 10, 2016; 7(1): 1-8
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.1
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.1
Neoadjuvant treatment for resectable pancreatic adenocarcinoma
John Wong, Chung-Tsen Hsueh, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92354, United States
Naveenraj L Solomon, Department of Surgery, Loma Linda University, Loma Linda, CA 92354, United States
Author contributions: Wong J, Solomon NL and Hsueh CT conceived the issues which formed the content of the manuscript and wrote the manuscript.
Conflict-of-interest statement: The author has no conflict of interests.
Correspondence to: Chung-Tsen Hsueh, MD, PhD, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, 11175 Campus Street, CSP 11015, Loma Linda, CA 92354, United States. chsueh@llu.edu
Telephone: +1-909-5584910 Fax: +1-909-5580219
Received: June 28, 2015
Peer-review started: July 11, 2015
First decision: August 16, 2015
Revised: November 6, 2015
Accepted: November 17, 2015
Article in press: November 25, 2015
Published online: February 10, 2016
Processing time: 216 Days and 11 Hours
Peer-review started: July 11, 2015
First decision: August 16, 2015
Revised: November 6, 2015
Accepted: November 17, 2015
Article in press: November 25, 2015
Published online: February 10, 2016
Processing time: 216 Days and 11 Hours
Core Tip
Core tip: The treatment of resectable pancreatic adenocarcinoma requires multidisciplinary approach and novel strategies including innovative trials to make progress. Data from completed neoadjuvant clinical trials are reviewed, and important ongoing studies are presented. Biomarkers for patient selection and personalized medicine are discussed.